FERMALAK ® capsules. vaginal., with applicator №10
Description FERMALAK ® capsules. vaginal., with the applicator:
FERMALAK ® (FERMALAC ®)
Pharmacological properties: FERMALAK capsules. vaginal., with applicator №10
Fermalak comes in the form of vaginal capsules containing lactic acid bacteria belonging to the normal microflora in the intestine and vagina and provide a protective function in women. Effect of the drug due to a combination of two ingredients Lactobacillus rhamnosus R0011 (1,6 x 109), and Yogurt Culture Rosell-94: Streptococcus thermophilus (0,2 x 109) and Lactobacillus delbrueckii subsp. Bulgaricus (0,2 x 109)
Yoghurt culture Rosell-94 regulates the acid balance in the vagina and prevents the reproduction of pathogenic and opportunistic microbes produces hydrogen peroxide, which inhibits the growth of anaerobic bacteria, pathogens of bacterial vaginosis; produces folic acid necessary for growth of lactobacillus vagina.
Lactobacillus rhamnosus R0011 have the exclusive ability to produce lactic acid and bacteriocins inhibit the growth of pathogenic bacteria, create optimal conditions for the restoration of normal vaginal microflora and its own local immunity.
Local or systemic treatment of vaginal infections with antibiotics and sulfonamides, hormonal therapy, improper hygiene violate and destroy the natural vaginal flora increase the risk of relapse. Therapeutic effect Fermalaka vaginal ensured by making active strains of lactic acid bacteria directly into the vagina and is manifested in the rapid decrease in pH of the vagina to 3,8-4,4; in the active suppression of growth and reproduction of pathogenic bacteria, restore proper vaginal microflora and the physiological balance in the vagina.
Lactose, which is contained in a vaginal capsules as a filler, also can be fermented into lactic acid, Lactobacillus. Ascorbic acid provides an antioxidant effect.
Reproduction of Lactobacillus and vaginal recolonization by these bacteria begins after the first use of the drug. They are capable of producing lactic acid to maintain acid balance in the vagina and prevent the proliferation of pathogenic and opportunistic microorganisms in the vagina, which can cause infectious and inflammatory diseases.
Fermalak used to restore and maintain normal vaginal microflora in the following cases:
• Prevention and treatment of specific and nonspecific vaginal infections;
• in the treatment of vaginitis caused by Trichomonas vaginalis and other pathogens (including vaginitis bacterial etiology);
• prevention of vulvovaginal candidiasis and vaginal dysbiosis;
• the use of different antibiotics, oral or vaginal contraceptives, as well as during chemotherapy;
• preoperative preparation for operations with vaginal access and prevention of postoperative infectious-inflammatory complications;
• before or after a local gynecologic interventions;
• as a preventive measure when using tampons, and local contraceptives, and inadequate hygiene.
In all the above cases, the patient can use the drug without medical control, however, with no effect on the treatment of inflammatory diseases during one week, should consult a physician.
From prevention to: 1-2 capsules of the drug is introduced into the vagina 1 time a week before going to bed. The application of this dosing scheme is expedient, for example, by using contraceptives.
For the treatment of vaginal infections and itching of the vagina: 1 capsule administered drug intravaginally 1 time per day at night before bed for 10 days.
From prevention to before or after gynecologic interventions: 1 capsule injected into the vagina once a day at night before bed for 10 days (use of the drug begin in the pre-intervention).
Capsule injected deep into the vagina using the included applicator. After each use should be carefully removed the piston from the applicator and rinse both sides of the device in warm water. After drying the applicator is ready for next use.
Hypersensitivity to any component of the drug.
in isolated cases, possible allergic reaction (itching may occur local to the vagina). Other side effects not described.
postmarketing studies of the drug during pregnancy was not performed. In clinical studies proved that Lactobacillus did not have an adverse effect on the course of the pregnancy or the health of the fetus / newborn. Therefore, the application Fermalaka during pregnancy is only possible by appointment at the doctor's discretion.
during treatment should refrain from vaginal douching with antiseptic p-ers, as they may reduce the effectiveness of the drug.
Storage: Store in a refrigerator at 2-8 ° C.